Evidence map›Paper›PMID 35410255›Full record

ArticleRespiratory research2022

Evaluation for clinical benefit of metformin in patients with idiopathic pulmonary fibrosis and type 2 diabetes mellitus: a national claims-based cohort analysis.

Taylor T Teague, Stephanie R Payne, Bryan T Kelly, Timothy M Dempsey, Rozalina G McCoy, Lindsey R Sangaralingham, Andrew H Limper

Registry-linked trialOpen access · goldFull text read
PubMed Full text at PMC Publisher
In one paragraph

Article in Respiratory research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06332612 (Repurposing Metformin for the Treatment of Oral Submucous Fibrosis), which is not on this map. Cited by 31 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 3 pooled it
5.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06332612 phase1 / phase2completednot on this mapstarted 2024, after this paper: background citation

Repurposing Metformin for the Treatment of Oral Submucous Fibrosis: Unraveling Novel Signaling Pathways In Vitro and Advancing to Clinical Trial"

TypeinterventionalSponsorZiauddin UniversityRan2024 to 2025Enrolled30ConditionsOral Submucous FibrosisArmsMetformin Hydrochloride, betamethasone dipropionate, Pentoxifylline
3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 3 syntheses or guidelines pooled it, 39 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Hallmarks of the ageing lung: 10 years later.The European respiratory journal · 2026
    Review
  6. Review
  7. Review
  8. Observational
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Senotherapy for chronic lung disease.Pharmacological reviews · 2025
    Review
  15. Article
  16. Review
  17. Silicosis: from pathogenesis to therapeutics.Frontiers in pharmacology · 2025
    Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Taylor T TeagueDivision of Pulmonary and Critical Care Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
Stephanie R PayneMayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Harwick Building, Second Floor, 200 First Street SW, Rochester, MN, 55905, USA.
Bryan T KellyDivision of Pulmonary and Critical Care Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
Timothy M DempseyDivision of Pulmonary and Critical Care Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
Rozalina G McCoyMayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Harwick Building, Second Floor, 200 First Street SW, Rochester, MN, 55905, USA.
Lindsey R SangaralinghamMayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Harwick Building, Second Floor, 200 First Street SW, Rochester, MN, 55905, USA.
Andrew H LimperDivision of Pulmonary and Critical Care Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. limper.andrew@mayo.edu.
Mayo Clinic · USMayo Clinic in Arizona · USOptum (United States) · US

Funding

Three Lakes Foundation TLF-1
6 · The paper itself

Abstract

backgroundIdiopathic pulmonary fibrosis (IPF) is a chronic progressive lung disease with high morbidity and limited treatment options. Type 2 diabetes mellitus (T2DM) is a common comorbid illness among patients with IPF and is often treated with metformin, the first-line agent in the management of T2DM. There is growing evidence demonstrating metformin's anti-fibrotic properties; however, there is little real-world clinical data regarding its potential effectiveness in IPF. This study aims to evaluate the clinical benefit of metformin in patients with IPF and T2DM.

methodsThis nationwide cohort study used de-identified administrative claims data from OptumLabs® Data Warehouse to identify 3599 adults with IPF and concomitant T2DM between January 1, 2014 and June 30, 2019. Two cohorts were created: a cohort treated with metformin (n = 1377) and a cohort not treated with metformin (n = 2222). A final 1:1 propensity score-matched cohort compared 1100 patients with IPF and T2DM receiving metformin to those with both diagnoses but not receiving metformin; matching accounted for age, sex, race/ethnicity, residence region, year, medications, oxygen use, smoking status, healthcare use, and comorbidities. Outcomes were all-cause mortality (primary) and hospitalizations (secondary).

resultsAmong 2200 patients with IPF and T2DM included in this matched analysis, metformin therapy was associated with a reduction in all-cause mortality (hazard ratio [HR], 0.46; 95% confidence interval [CI], 0.36-0.58; p < 0.001) and hospitalizations (HR, 0.82; 95% CI, 0.72-0.93; p = 0.003) compared to patients not receiving metformin.

conclusionsAmong patients with IPF and T2DM, metformin therapy may be associated with improved clinical outcomes. However, further investigation with randomized clinical trials is necessary prior to metformin's broad implementation in the clinical management of IPF.

Indexed as

Diabetes Mellitus, Type 2Idiopathic Pulmonary FibrosisMetforminAdultCohort StudiesHumansInsurance Claim ReviewRetrospective StudiesMetforminHospitalizationIdiopathic pulmonary fibrosisInterstitial lung diseaseMetforminMortalityType 2 diabetes mellitus

Identifiers

PMID35410255
PMCPMC9004115
OpenAlexW4223415260

What OpenQuestion holds

Textfull text, public
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.